Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brookfield Infrastructure Partners LP (BIP) vs Cassava Sciences Inc (FLNA) Price & Performance

Brookfield Infrastructure Partners LPTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Brookfield Infrastructure Partners LP vs Cassava Sciences Inc — how do they compare? Brookfield Infrastructure Partners LP trades at $38.19 (market cap $17.38B), while Cassava Sciences Inc trades at $1.11 (market cap $52.66M). The key difference: Brookfield Infrastructure Partners LP is far larger — about 330× Cassava Sciences Inc's market cap, and Brookfield Infrastructure Partners LP pays a 4.77% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

BIPFLNA
Market Cap
$17.38B$52.66M
Sector
IndustrialsHealth
52-Week High
$40.08$4.64
52-Week Low
$29.81$1.09
Enterprise Value
$79.06B-$33.92M
Dividend Yield
4.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brookfield Infrastructure Partners LP

Brookfield Infrastructure Partners (BIP) trades at $37.61, down slightly by 0.11% today. The stock shows bullish technical signals with strong analyst support (81% buy ratings) and a $45.50 consensus price target. Recent earnings have been mixed with one beat and two misses, but the company maintains robust cash flows with $5.97B from operations in 2025. BIP offers a 5% dividend yield with recent H1-26 payment of $0.46 per share.

BIP presents a compelling value opportunity with discounted valuation metrics (P/S 0.73, EV/EBITDA 7.55) and strong infrastructure assets. However, investors face risks from recent earnings volatility, high P/E ratio of 57.8, and declining profit margins. The company's global infrastructure portfolio provides inflation protection and stable cash flows, supporting the bullish analyst consensus despite near-term headwinds.

Cassava Sciences Inc

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Brookfield Infrastructure Partners LP

Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.

Read more on BIP

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA